Patents by Inventor Xiaojie Zhu

Xiaojie Zhu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210347779
    Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
    Type: Application
    Filed: January 5, 2021
    Publication date: November 11, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Wanjun ZHENG, Xiaojie ZHU, Hong DU, Maarten POSTEMA, Yimin JIANG, Jing LI, Robert YU, Hyeong-Wook CHOI, Jaemoon LEE, Francis G. FANG, Daniel CUSTAR
  • Patent number: 10941148
    Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: March 9, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Wanjun Zheng, Xiaojie Zhu, Hong Du, Maarten Postema, Yimin Jiang, Jing Li, Robert Yu, Hyeong-wook Choi, Jaemoon Lee, Frank Fang, Daniel Custar
  • Publication number: 20190315754
    Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
    Type: Application
    Filed: April 23, 2019
    Publication date: October 17, 2019
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Wanjun Zheng, Xiaojie Zhu, Hong Du, Maarten Postema, Yimin Jiang, Jing Li, Robert Yu, Hyeong-wook Choi, Jaemoon Lee, Frank Fang, Daniel Custar
  • Patent number: 10316040
    Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: June 11, 2019
    Assignee: Eisai R&D Management Co., LTD.
    Inventors: Wanjun Zheng, Xiaojie Zhu, Hong Du, Maarten Postema, Yimin Jiang, Jing Li, Robert Yu, Hyeong-wook Choi, Jaemoon Lee, Frank Fang, Daniel Custar
  • Publication number: 20180305362
    Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
    Type: Application
    Filed: October 14, 2016
    Publication date: October 25, 2018
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Wanjun Zheng, Xiaojie Zhu, Hong Du, Maarten Postema, Yimin Jiang, Jing Li, Robert Yu, Hyeong-wook Choi, Jaemoon Lee, Frank Fang, Daniel Custar
  • Publication number: 20120029213
    Abstract: Intermediates and methods of their use in the synthesis of analogs of halichondrin B are provided.
    Type: Application
    Filed: June 29, 2011
    Publication date: February 2, 2012
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Brian Austad, Farid Benayoud, Trevor Calkins, Silvio Campagna, Charles E. Chase, William Christ, Francis G. Fang, Yongbo Hu, Bryan M. Lewis, Marc Pesant, Matthew Schnaderbeck, Gordon Wilkie, Xiaojie Zhu
  • Publication number: 20050228039
    Abstract: The present invention provides compounds having formula (I) (and pharmaceutically acceptable derivatives thereof): and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of cancer, wherein R1-R14 and n are as defined herein.
    Type: Application
    Filed: December 18, 2002
    Publication date: October 13, 2005
    Inventors: Francis Fang, Charles Johannes, Ye Yao, Xiaojie Zhu
  • Patent number: RE47797
    Abstract: Intermediates and methods of their use in the synthesis of analogs of halichondrin B are provided.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: January 7, 2020
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Farid Benayoud, Trevor Lee Calkins, Charles E. Chase, William Christ, Bryan M. Lewis, Matthew Schnaderbeck, Marc Pesant, Brian Austad, Silvio Campagna, Yongbo Hu, Gordon Wilkie, Xiaojie Zhu, Francis G. Fang
  • Patent number: D947856
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: April 5, 2022
    Assignee: Shenzhen Bluefinger Electronics Co., Limited
    Inventor: Xiaojie Zhu